- Home
- MMD vs CMPX Comparison
MMD vs CMPX Comparison
Compare MMD & CMPX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MMD
- CMPX
- Stock Information
- Founded
- MMD 2012
- CMPX 2014
- Country
- MMD United States
- CMPX United States
- Employees
- MMD N/A
- CMPX N/A
- Industry
- MMD Investment Managers
- CMPX Biotechnology: Pharmaceutical Preparations
- Sector
- MMD Finance
- CMPX Health Care
- Exchange
- MMD Nasdaq
- CMPX Nasdaq
- Market Cap
- MMD 276.1M
- CMPX 291.8M
- IPO Year
- MMD N/A
- CMPX N/A
- Fundamental
- Price
- MMD $14.64
- CMPX $2.95
- Analyst Decision
- MMD
- CMPX Strong Buy
- Analyst Count
- MMD 0
- CMPX 9
- Target Price
- MMD N/A
- CMPX $12.67
- AVG Volume (30 Days)
- MMD 74.7K
- CMPX 735.9K
- Earning Date
- MMD 01-01-0001
- CMPX 08-11-2025
- Dividend Yield
- MMD 4.88%
- CMPX N/A
- EPS Growth
- MMD N/A
- CMPX N/A
- EPS
- MMD N/A
- CMPX N/A
- Revenue
- MMD N/A
- CMPX $850,000.00
- Revenue This Year
- MMD N/A
- CMPX N/A
- Revenue Next Year
- MMD N/A
- CMPX N/A
- P/E Ratio
- MMD N/A
- CMPX N/A
- Revenue Growth
- MMD N/A
- CMPX N/A
- 52 Week Low
- MMD $14.30
- CMPX $0.87
- 52 Week High
- MMD $17.67
- CMPX $4.08
- Technical
- Relative Strength Index (RSI)
- MMD 50.88
- CMPX 52.25
- Support Level
- MMD $14.43
- CMPX $3.11
- Resistance Level
- MMD $14.73
- CMPX $3.35
- Average True Range (ATR)
- MMD 0.15
- CMPX 0.20
- MACD
- MMD -0.00
- CMPX -0.04
- Stochastic Oscillator
- MMD 62.82
- CMPX 23.07
About MMD MainStay MacKay DefinedTerm Municipal Opportunities Fund
NYLI MacKay DefinedTerm Muni Opportunities Fund is a USA-based diversified closed-end management investment company. The fund's investment objective is to seek current income exempt from regular U.S. Federal income taxes as well as total return. The company predominantly invests in municipal bonds, the interest on which is, in the opinion of bond counsel to the issuers, generally excludable from gross income for regular U.S. Federal income tax purposes.
About CMPX Compass Therapeutics Inc.
Compass Therapeutics Inc is a clinical-stage biopharmaceutical company that develops proprietary antibody therapeutics to engage the immune system to treat solid tumors and hematological malignancies. It is engaged in drug discovery by leveraging its proprietary antibody discovery engine to drug the immune system and identify optimal combinations empirically broadly. Through StitchMabs and common light chain platforms, these combinatorial insights can be rapidly translated into tailored bispecifics with monoclonal-like manufacturability. Its pipeline is comprised of the following product candidates; CTX-009, CTX-471, CTX-10726, VEGF-IO Bispecific, and CTX-8371.